Find out more about the NICE Diagnostics Advisory Committee members by reading their biographies.
Dr Mark Kroese MB, ChB, DPH, FFPH, FRCP(Ed), MRCGP
Consultant in Public Health Medicine, PHG Foundation
Mark Kroese is a Consultant in Public Health Medicine at the PHG Foundation, Cambridge and was appointed Public Health Advisor to the UK Genetic Testing Network in 2006. Prior to joining the PHG Foundation, Mark worked for nearly 7 years as Consultant in Public Health Medicine at Peterborough Primary Care Trust.
His specialist interests are in the evaluation and regulation of genetic tests and the commissioning of clinical genetics services.
Ms Elizabeth Adair
Quality Director, Viapath Group LLP
Liz Adair is a qualified nurse with extensive senior management experience in the NHS, where she worked for over 32 years. She is the Director for Quality at Viapath Group LLP, a joint venture pathology services provider, where she is the lead for clinical governance assurance and quality standards.
She undertook her nursing training in London, initially at the Nightingale School of Nursing at St Thomas’ Hospital, before moving to Guy’s Hospital and qualifying as a sick children’s nurse. She developed an interest in family mental health, qualifying as a mental health nurse in Bloomsbury Health Authority. Liz’s clinical practice was predominately in child & adolescent mental health services in South East London.
In the early 1990’s, Liz moved from her clinical work into a range of operational roles, initially at the South London and Maudsley NHS Foundation Trust. She transitioned into acute care and has extensive NHS senior management experience from a number of roles, including Associate Director for emergency care, medicine, women’s, children’s and older peoples services in East Anglia. Liz particularly enjoys working with health, social care providers and patients, in developing multi-agency patient focused strategy, redesign and implementation of system–wide care pathways.
Graduating in 2016 at Henley Business School, University of Reading with a Master of Business Administration (MBA) degree, Liz has developed an extensive cross sector network and range of interests. This includes her appointment and active participation as a Trustee of Carers Network, a charity offering support to unpaid carers in a number of London boroughs.
Mr John Bagshaw
In-Vitro Diagnostics Consultant
John Bagshaw is one of two industry representatives on the DAC. He worked for 36 years for diagnostic companies in various roles after initial employment as Company Microbiologist for a manufacturer of dialysis and transfusion equipment.
Now a freelance consultant, he is also a Public Governor for an NHS Foundation Hospital Trust and a member of the West Berkshire Patient Group and of the Mortimer Surgery Patient Panel.
John maintains his interest in In Vitro Diagnostics through membership of the Executive Board of the British In Vitro Diagnostic Association (BIVDA) and chairmanship of the Market Dynamics working group which also involves membership of the Market Research Committee of MedTech Europe.
Professor Enitan Carrol
Chair in paediatric infection and honorary consultant in paediatric infectious diseases, Alder Hey Children's Hospital
Enitan qualified from The University of Aberdeen in 1989. She then commenced general medicine training before switching to paediatric training in Manchester, Liverpool and Newcastle. Her doctoral thesis was on meningococcal sepsis in children. Following this she completed specialist training in paediatric infectious diseases. A lectureship at the University of Liverpool was followed by a Wellcome Trust Career Development Fellowship on invasive pneumococcal disease in Malawian children. She returned to Liverpool to take up a senior clinical lectureship in 2007, and was awarded a Chair in paediatric infection in 2013.
Her research interests include bacterial infections in children, diagnostic accuracy studies, testing of biomarker panels and early warning scores for early recognition. She has over 20 years’ experience of clinical research in hospitalised children with infections. She works closely with a number of industry partners on collaborative research projects.
She was a member of our guideline development committee for sepsis and a specialist member on the diagnostic advisory committee for procalcitonin testing.
Dr Owen Driskell
Owen Driskell is a Clinical Scientist and the Clinical Academic Science Manager at the National School for Healthcare Science with responsibilities for Clinical Academic Development of Healthcare Scientists in the NHS. He trained and worked as a Clinical Biochemist in NHS pathology laboratories for over 10 years before joining the NIHR Clinical Research Network West Midlands as Lead for Laboratory Medicine in 2015. In this role he championed professionalism in pathology research and promoted the contribution and importance of pathology contributions to NHS research. This involved supporting the development of both the pathology services provided for NHS research and the research led by pathology laboratory professionals.
Owen’s research interests are in diabetes and the use of laboratory tests. His Clinical Scientist training included the award and completion of an inaugural NIHR CSO HCS Fellowship assessing the use of HbA1c in the monitoring of patients with Diabetes Mellitus. During this time he developed an interest in the use of evidence to inform laboratory practice.
Dr James William Gray
Consultant Microbiologist, Department of Microbiology, Birmingham Children’s Hospital
Jim Gray has been a Consultant Microbiologist at Birmingham Children’s and Women’s Hospitals since 1995. Clinical and research interests include diagnostic test accuracy studies and improving the laboratory-clinical interface, in particular to ensure that key laboratory results are reported and appropriately acted upon without delay.
Recent service innovations include the introduction of Advance Laboratory Practitioners, multidisciplinary laboratory working to support infection control and antibiotic decision making on an out of hours basis. Research interests include point of care testing for group B streptococcus screening in labouring women and improved blood culture technology to support antibiotic stewardship in neonates.
Jim has worked on several NICE Programmes, including being a member of two Guideline Development Groups and a Standing Member of a Rapid Clinical Guideline Updates Committee. He is an Expert Advisor for the British National Formulary for Children (BNF-C), and has served on a number of national committees relating to paediatric infectious diseases and antibiotic treatment. He is Editor-in-Chief of The Journal of Hospital Infection and an Assistant Editor of International Journal of Antimicrobial Agents and the Journal of Pediatric Infectious Diseases.
Dr Shelley Rahman Haley
Consultant Cardiologist, Royal Brompton and Harefield NHS Foundation Trust
Biography to follow.
Professor Steve Halligan
Professor of Radiology, University College London
Professor Steve Hallligan is an academic clinical radiologist working at UCL and UCLH. His clinical work revolves around gastrointestinal and breast imaging. He is a Fellow of the Academy of Medical Sciences and NIHR Senior Investigator Emeritus. He has been President of both the European and British Societies of Gastrointestinal and Abdominal Radiology.
He is Head of the Department of Imaging at UCL and has specific expertise in multi-centre pragmatic trials of imaging interventions within the NHS, for which he has received substantial funding from various NIHR Programmes. He also supervises systematic reviews and meta-analyses of diagnostic tests and obtained a PhD in 2015, related to statistical alternatives to ROC curve analysis.
Professor Neil Hawkins
Professor of Health Technology Assessment, University of Glasgow
Neil Hawkins is a Professor of Health Technology Assessment (HTA) at the University of Glasgow, Scotland. He is deputy director of the National Institute of Health Research (NIHR) funded Complex Reviews Support Unit (CRSU). His research interests include methods development for evidence synthesis and decision-analytic modelling and the use of “development focussed” HTA to support decision-making regarding the development of, and investment in, nascent healthcare technologies.
He holds post-graduate degrees in Pharmacology, Health Economics and Applied Statistics and an MBA. He has worked in the pharma, academic, and consultancy sectors in roles spanning basic pharmacological research, clinical development, epidemiology, and health technology assessment.
Mr John Hitchman
John Hitchman is a retired Chartered Architect who was Principal of a private practice in Co. Durham. He has served on standard committees for a number of statutory and voluntary organisations and currently sits on the Lord Chancellor's Advisory Committee for the Selection of Magistrates. John is a member of the Lay Group of the Royal College of Anaesthetists where he serves on a range of the College's committees. He is also the lay representative on Peer Review Panels for the Association of Paediatric Anaesthetists of Great Britain and Ireland. John's particular interest in the NHS is the improvement of the patient experience especially for the young and the vulnerable.
Professor Chris Hyde
Professor of Public Health & Clinical Epidemiology, Exeter Test Group, University of Exeter Medical School
Chris Hyde trained in medicine and public health in London and East Anglia respectively. His expertise is in systematic reviews and health technology assessments, particularly in the context of providing support to policy-makers. In this respect he has undertaken many reports for NICE, particularly its Technology Appraisal Programme.
During his career he has set up and directed the Aggressive Research Intelligence Facility (ARIF), an effectiveness information support service for commissioners in the West Midlands. Chris has also directed the West Midlands Health Technology Assessment Collaboration and been closely involved with the Systematic Reviews Initiative of the National Blood Service. He has long-standing connections with the Cochrane Collaboration and is an editor of the NHS HTA Monograph series. He is currently based at the Peninsula College of Medicine and Dentistry where he leads the Technology Appraisal Group in PenTAG.
He has a long-standing interest in the evaluation of tests and has done health technology assessments on many topics including automated cervical screening, hysteroscopy, prediction of pre-eclampsia and pre-term birth, PET/CT, orthopantomography and identifying genetic sub-types in diabetes. He is currently part of the UK Support Unit for Cochrane Diagnostic Test Accuracy Reviews based at the University of Birmingham; and a member of the Cochrane Diagnostics Test Accuracy Editorial Board.
Dr Sandeep Kapur BSc(Hons) MBBS MRCGP(Dist)
GP, south east London
Dr Sandeep Kapur is a GP in south east London. He undertook medical training at Guys & St Thomas’ Hospitals following which he completed an Internal Medicine training program from Case Western Reserve University, Cleveland, USA. He is a GMC PLAB examiner, CQC GP specialist advisor and is a member of the BNF Joint Formulary committee.
Mr Patrick McGinley ICMA, CGMA
Head of Costing and Service Line Reporting, Maidstone and Tunbridge Wells NHS Trust
Patrick started as a Trainee Accountant at St Bartholomew’s Hospital in 1983, and apart from a brief sojourn to the far NW of Scotland as a postmaster, has worked in the NHS ever since in a variety of roles and institutions including at the Royal London, Homerton, Whipps Cross and Great Ormond Street before moving to Maidstone & Tunbridge Wells
He is currently Head of Costing and SLR, and has implemented an automated system of calculating costs at a patient level, and firmly believes that improved costing can help the NHS to understand its business, and maximise the value of healthcare.
He has direct operational experience as a Programme Manager of an NHS Breast Screening Unit, to go with experience as a Management and Costing Accountant, and he has successfully completed two PFI projects (BLT and TWH) as financial lead to offset the significant number of hospitals that he has helped to shut over his career.
He is an active member of the HFMA Costing Special Interest Group, and is also a member of NHSI’s Costing Advisory Group and technical review group, is a reviewer for both NICE and NIHR, and has presented regularly at National events on Acute Costing Standards.
He was a member of tariff calculation groups for NCAT for Chemotherapy and Radiotherapy, is a Fellow of Royal Statistical Society and a member of HSUG. He lectures on statistics for journalists for RSS. He benchmarks costing approaches with international colleagues, and is a training mentor for the Chartered Institute of Management Accountants; understandably, he is therefore rarely allowed out on his own.
Dr Michael Messenger
Deputy Director and Scientific Manager - NIHR Diagnostic Evidence Co-operative Leeds
Dr Michael Messenger is the Deputy Director and Scientific Manager for the NIHR Diagnostic Evidence Co-Operative Leeds and is responsible for overseeing the delivery of high-quality scientific evidence on in-vitro diagnostics (IVD) for the NHS.
As the Principal Healthcare Scientist on a NIHR Applied Programme Grant for Research “Evaluating the benefits for patients and the NHS of new and existing biological fluid biomarkers in liver and renal disease” he has experience across many phases of the “diagnostic pipeline” including the development, validation and clinical evaluation of new diagnostic assays.
Mrs Alexandria Moseley
Alexandria holds a degree in International Finance from the Wharton School as well as a degree in product design from FIT in New York City. She has been a Wall Street trader, serial entrepreneur, business owner, industry consultant, lifestyle blogger, and health advocate.
Served for many years as an international lay reviewer for Juvenile Diabetes Research Foundation and as a member of the Diabetes Research Network, plus one year on the Lay Committee for Diabetes UK. Invited as a patient expert for two previous NICE committees formulating guidance on insulin pumps. She has a special interest in autoimmune diseases.
Dr Simon Richards PhD
VP, Regulatory Affairs, EME, Alere
Simon Richards is VP, regulatory Affairs EME for Alere. Originally a PhD Biochemist working on chemiluminescent assay techniques, he has worked in the Vaccines and Diagnostics industry for over 20 years. He began his career at Amersham/Johnson+Johnson as a scientist before transitioning into Quality and Regulatory roles of increasing seniority in DPC (now part of Siemens), Novartis, Axis-Shield and now Alere.
He is also the chair of the Regulatory Affairs Working party for the UK IVD Industry body, BIVDA.
Professor Mark Sculpher BA (Hons), MSc, PhD
Professor of Health Economics, Centre for Health Economics, University of York
Mark Sculpher has worked in the field of economic evaluation and health technology assessment for over 25 years. He has researched in a range of clinical areas including heart disease and cancer, and evaluated therapeutic and diagnostic technologies He has also contributed to methods in the field, in particular relating to decision analytic modelling and techniques to handle uncertainty. He has over 200 peer-reviewed publications and is a co-author of two major textbooks in the area.
Mark is a member of the UK National Institute of Health Research (NIHR) College of Senior Investigators. He has also been a member of the NICE Technology Appraisal and Public Health Interventions Advisory Committees. He chaired NICE's 2004 Task Group on methods guidance for economic evaluation; and has also advised health systems internationally on HTA methods including those in Ireland, Portugal, France and New Zealand. He has been a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme and currently sits on the UK Medical Research Council's Methodology Research Panel.
Professor Matt Stevenson BSc, PhD
Director of the School of Health and Related Research Technology Assessment Group
Matt studied Operational Research at Lancaster University where he received his doctorate. He worked for the University of Sheffield for over 20 years, during which time he conducted cost-effectiveness analyses primarily for the National Institute for Health Research.
Matt is Director of the School of Health and Related Research Technology Assessment Group, an academic group undertaking modelling work to provide data for NICE technology and diagnostic appraisals. He is also a member of our technology appraisal committee, as well as our decision support unit.
Professor Anthony Wierzbicki BA, MA, BM, BCh, DPhil, DM
Consultant in Metabolic/Chemical Pathology, St Thomas Hospital
Professor Anthony Wierzbicki is a consultant in metabolic medicine & chemical pathology and has been director of the lipid unit at St. Thomas and Guy’s Hospitals in 1994. His work in the field of atherosclerosis has led to appointments as a Fellow of the National Association of Clinical Biochemistry (USA) and the American Heart Association (arteriosclerosis and blood pressure sections). He has been a trustee of HEART-UK (the UK cholesterol charity) and chairman of this charity’s medical and scientific committee.
His clinical interests are in diagnostics, cardiovascular risk quantification systems and the molecular genetics of hyperlipidaemia. He is a member of the SE London cardiac network treatment and vascular risk guideline groups.
He was a member of the writing group of the International Familial Hypercholesterolaemia guidelines. He has served at NICE on Technology Appraisal panels, the familial hypercholesterolaemia guideline group (CG71) and chaired the Lipids and Cardiovascular risk assessment guideline (CG181).